Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

P-023

Supelco

Phentermine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H15N
Número de CAS:
122-09-8
Peso molecular:
149.23
MDL number:
MFCD00059195
UNSPSC Code:
41116107
PubChem Substance ID:
329820023
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

SMILES string

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

InChI key

DHHVAGZRUROJKS-UHFFFAOYSA-N

Categorías relacionadas

General description

A Snap-N-Spike® reference solution applicable for use in clinical toxicology or urine drug testing by LC-MS/MS or GC/MS. Phentermine, a phenethylamine analog, is a stimulant and an appetite suppressant. This drug is a constituent of the withdrawn anti-obesity medication fen-phen.

Application

  • Phentermine solution for weight loss research: Phentermine is extensively studied as an appetite suppressant in obesity treatment. Its effectiveness in weight loss regimens is often analyzed through pharmaceutical research, where the solution form facilitates precise dosing and control in clinical trials, enhancing the understanding of its pharmacodynamics and therapeutic potential (Ni et al., 2015).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Eva Manakova et al.
Neuro endocrinology letters, 33 Suppl 3, 179-182 (2013-01-29)
Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is
Prescrire international, 22(136), 61-64 (2013-04-18)
The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise. There are no drugs with a favourable harm-benefit balance in this setting. A fixed-dose combination of topiramate, an antiepileptic drug, and
Two new drugs approved for obesity.
Annette M Johnson
South Dakota medicine : the journal of the South Dakota State Medical Association, 65(9), 356-357 (2012-10-17)
Fiona Cameron et al.
Drugs, 72(15), 2033-2042 (2012-10-09)
Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed
David H Winslow et al.
Sleep, 35(11), 1529-1539 (2012-11-02)
To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults. This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico